Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia

Introduction: Respiratory syncytial virus (RSV) is one of the most important childhood infections. Objective: To evaluate the effectiveness and safety of palivizumab immunoprophylaxis in preterm infants at a high risk of severe respiratory syncytial virus infection during the RSV season in Colombia...

Full description

Bibliographic Details
Published in:	Journal of Infection in Developing Countries
Main Authors:	Juan Gabriel Piñeros, Jose De la Hoz-Valle, Clara Galvis, Astrid Celis, Oscar Ovalle, Carmen Cecilia Sandoval, Jaime Orrego, Saby Vides, Iader Rojas, Hernando Bustamante, Carlos Gallón, Jaime Alberto Mesa
Format:	Article
Language:	English
Published:	The Journal of Infection in Developing Countries 2021-11-01
Subjects:	Palivizumab Prophylaxis Respiratory syncytial virus Lower respiratory tract infectio
Online Access:	https://jidc.org/index.php/journal/article/view/12561

Similar Items

Adherence to Palivizumab for Respiratory Syncytial Virus Prophylaxis in Romanian Infants
by: Andreea Calomfirescu-Avramescu, et al.
Published: (2025-02-01)

One‐year observational study of palivizumab prophylaxis on infants at risk for respiratory syncytial virus infection in Latin America
by: Leandro Martin Castillo, et al.
Published: (2017-09-01)

Palivizumab for Severe Respiratory Syncytial Virus Infection in Immunocompetent Adults: A Case Series
by: Zhong JY, et al.
Published: (2025-08-01)

Palivizumab for the Prophylaxis of Respiratory Syncytial Virus Disease: Expert Opinion and Recommendations for the Gulf Cooperation Council Region
by: Adel S. Alharbi, et al.
Published: (2024-09-01)

Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
by: Hasindu S. Edirisinghe, et al.
Published: (2023-11-01)

Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro
by: Envera Lekic, et al.
Published: (2024-05-01)

Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia
by: Jaime E. Ordóñez, et al.
Published: (2024-04-01)

Recommendation for immune prophylaxis of respiratory syncytial virus infection in children
by: Ping-Ing Lee, et al.
Published: (2025-06-01)

IMMUNOPROPHYLAXIS OF SEVERE RESPIRATORY-SYNCYTIAL VIRAL INFECTION IN CHILDREN WITH BRONCHOPULMONARY DYSPLASIA: RESULTS OF 4 EPIDEMIC SEASONS
by: A. A. Baranov, et al.
Published: (2012-12-01)

Immunoprophylaxis of Respiratory Syncytial Virus Infection in Children
by: A. A. Baranov, et al.
Published: (2015-12-01)

Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children
by: Natividad Viguria, et al.
Published: (2021-06-01)

Effect of an In-Home Palivizumab Administration Program for Children with Medical Complexity
by: Hina Emanuel, et al.
Published: (2024-09-01)

Regional impact of prophylaxis with the monoclonal antibody palivizumab on ospitalizations from respiratory syncytial virus in infants
by: Swiss Medical Weekly
Published: (2001-03-01)

Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: systematic review and additional economic modelling of subgroup analyses
by: D Wang, et al.
Published: (2011-01-01)

Cost-effectiveness of nirsevimab and palivizumab for respiratory syncytial virus prophylaxis in preterm infants 29–34 6/7 weeks' gestation in the United States
by: Tianzhou Yu, et al.
Published: (2024-03-01)

A post-incorporation study on the use of palivizumab in the Brazilian public health system
by: Joanna d’Arc Lyra Batista, et al.
Published: (2021-01-01)

Cost effectiveness of a protocol using palivizumab in preterm infants
by: Yolanda Hernández-Gago, et al.
Published: (2017-03-01)

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
by: Bernhard Resch
Published: (2017-09-01)

A practical guidance on the prevention and treatment of childhood respiratory syncytial virus infection in Kurdistan
by: Azad A. Haleem, et al.
Published: (2025-03-01)

Prevention of respiratory syncytial virus infection in children. Recommendations of the Polish Society of Paediatrics and the National Paediatric Consultant
by: Teresa Jackowska, et al.
Published: (2024-12-01)

Resurgence of Respiratory Syncytial Virus in Children: An Out-of-Season Epidemic in Portugal
by: Ana Rita Torres, et al.
Published: (2023-01-01)

Respiratory syncytial virus seasonality in Brazil: implications for the immunisation policy for at-risk populations
by: André Ricardo Ribas Freitas, et al.
Published: (2016-01-01)

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children
by: Saleh al-Alaiyan, et al.
Published: (2015-02-01)

Respiratory Morbidity in Prematurely Born Children Receiving Palivizumab Prophylaxis of Respiratory Syncytial Virus Disease
by: Milena Bjelica, et al.
Published: (2024-04-01)

Respiratory syncytial virus immunization patterns in Germany, 2015–2020
by: Moritz Wick, et al.
Published: (2024-12-01)

Respiratory syncytial virus under 2 years of age: hospitalization trends and risk factors for severe disease â preliminary data from the Portuguese sentinel network
by: Ana R. Torres, et al.
Published: (2024-01-01)

The Impact of Palivizumab for Respiratory Syncytial Virus Prophylaxis on Preschool Childhood Asthma
by: Hannah Ora Hasson, et al.
Published: (2024-11-01)

Respiratory syncytial virus immunization in children: The old, the new and what’s just around the corner
by: Bosco A. Paes, et al.
Published: (2025-12-01)

Temporal-spatial analysis of hospitalizations for bronchiolitis in Brazil: prediction of epidemic regions and periods for immunization against the Respiratory Syncytial Virus
by: Edilenia Queiroz Pereira, et al.
Published: (2023-03-01)

IMMUNOPTOPHYLAXIS OF THE RESPIRATORY SYNCYTIAL VIRAL INFECTION IN CHILDREN UNDER RISK OF HEAVY COURSE OF THE DISEASE: PRELIMINARY RESULTS OF IMPLEMENTING THE MOSCOW PROGRAM
by: A. A. Korsunskiy, et al.
Published: (2012-06-01)

Challenges in the prophylaxis of severe respiratory syncytial virus infections
by: Dana C. Feitosa, et al.
Published: (2025-09-01)

A CLINICAL AND ECONOMICAL ANALYSIS OF THE RESULTS PRODUCED BY THE PROGRAM OF RSV-INFECTION PROPHYLAXIS DURING THE EPIDEMIOLOGICAL SEASON OF 2012/2013 IN MOSCOW
by: V. I. Ignat'eva, et al.
Published: (2013-11-01)

Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue
by: Qianqian Li, et al.
Published: (2024-12-01)

Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010
by: Jesse Papenburg, et al.
Published: (2012-01-01)

Respiratory syncytial virus infection as a cause of hospitalization in population under 1 year in Colombia
by: Juan Gabriel Piñeros, et al.
Published: (2013-11-01)

Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan
by: Naruhiko Ishiwada, et al.
Published: (2024-06-01)

Modern Approaches in management of Children with Acute Bronchiolitis
by: Alexander A. Baranov, et al.
Published: (2020-02-01)

RESPIRATORY SYNCYTIAL VIRUS INFECTION IN INFANTS
by: K. V. YEVDOKIMOV, et al.
Published: (2017-05-01)

THE EFFICACY OF THE COSTS ON SEVERE RESPIRATORY SYNCYTIAL INFECTION PREVENTION WITH PALIVIZUMAB IN PRETERM INFANTS
by: A. V. Rudakova, et al.
Published: (2012-07-01)

Update to: Study Pre-protocol for “BronchStart - The Impact of the COVID-19 Pandemic on the Timing, Age and Severity of Respiratory Syncytial Virus (RSV) Emergency Presentations; a Multi-Centre Prospective Observational Cohort Study” [version 3; peer review: 2 approved]
by: Mark D. Lyttle, et al.
Published: (2024-10-01)